Coronary artery obstruction is a life-threatening complication of transcatheter aortic valve replacement procedures, and current preventive strategies are suboptimal. The novel ShortCut device splits bioprosthetic valve leaflets that are at risk of causing coronary artery obstruction after transcatheter aortic valve implantation, allowing for normal coronary flow. In this video tutorial, we demonstrate a valve-in-valve transcatheter aortic valve implantation using a dedicated leaflet-splitting device for prevention of coronary artery obstruction in transcatheter aortic valve replacement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1510/mmcts.2022.105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Strategic Management of Valve Infolding in Evolut TAVR Procedures: Enhancing Outcomes and Ensuring Patient Safety.
J Soc Cardiovasc Angiogr Interv
December 2024
Cardiovascular Institute, Detroit Medical Center, DMC Heart Hospital, Detroit, Michigan.
Transcatheter aortic valve repair (TAVR) presents a minimally invasive alternative to traditional surgical valve replacement, albeit not without its own set of complications. A rare complication is the infolding of the self-expanding valve, which can precipitate cardiac arrest. The estimated incidence rate of this complication stands at 1.
View Article and Find Full Text PDFManagement of Acute Coronary Syndrome in Patients With Transcatheter Aortic Valve Replacement: A Review.
Catheter Cardiovasc Interv
January 2025
Department of Medicine, Michael E DeBakey Veteran's Affairs Medical Center, Houston, Texas, USA.
Transcatheter aortic valve replacement (TAVR) has become a viable treatment option for patients with severe aortic stenosis among all risk subsets. As TAVR use becomes more prevalent and patients live longer with their transcatheter valve, an increasing number of these patients can be expected to present with ACS. Overall, there is a paucity of high-quality data detailing incidence, pathophysiology, and management of ACS in this subset.
View Article and Find Full Text PDF[The improvement effects of TAVR on cardiac electrical remodeling of patients with severe aortic stenosis].
Zhonghua Xin Xue Guan Bing Za Zhi
January 2025
Cardiology Department, Second Affiliated Hospital of Dalian Medical University, Dalian116021, China.
To assess the effectiveness of transcatheter aortic valve replacement (TAVR) on electrocardiographic remodeling in patients with severe aortic stenosis (AS), and identify its influencing factors. A cohort study was conducted on patients with a confirmed diagnosis of severe AS who successfully underwent TAVR at the Second Affiliated Hospital of Dalian Medical University between June 2018 and March 2023. Data, including standard 15-lead electrocardiograms and echocardiograms, were collected before the operation, 1 week after the operation, and 3 months after the operation.
View Article and Find Full Text PDFBackground: Surgical aortic valve replacement (SAVR) is the commonly used approach for aortic valve replacement (AVR) in patients with aortic stenosis at low or intermediate surgical risk. However, transcatheter aortic valve replacement (TAVR) has emerged as an alternative to SAVR for AVR. This meta-analysis aims to assess the comparative efficacy and safety of TAVR versus SAVR in low-to-intermediate surgical risk patients by analyzing temporal trends in the outcomes of TAVR and SAVR at various follow-up intervals, providing a more detailed understanding.
View Article and Find Full Text PDFCorrection: SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI).
Cardiovasc Diabetol
January 2025
Division of Cardiology, Sant'Andrea Hospital, Rome, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!